In 2017, MDA helped thousands of families live better and longer lives. All of this and much more was possible thanks to you. Thank you for helping MDA make 2017 a remarkable year for the families we serve.
Solid Biosciences announced the launch of its first clinical trial for SGT-001. The phase 1/2 study, called IGNITE DMD, is designed to assess safety and efficacy of a single dose of SGT-001 in children and adolescents with DMD.